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Abstract  19 
Vaccinia virus (VACV) strain Western Reserve gene A49L encodes a small, intracellular protein with a Bcl-2 fold 20 
that is expressed early during infection and has multiple functions. A49 co-precipitates with the E3 ubiquitin 21 
ligase β-TrCP and thereby prevents ubiquitylation and proteasomal degradation of IκBα, and consequently 22 
blocks activation of NF-κB. In a similar way, A49 stabilises β-catenin, leading to activation of the wnt signalling 23 
pathway. However, a VACV strain expressing a mutant A49 that neither co-precipitates with β-TrCP nor inhibits 24 
NF-κB activation, is more virulent than a virus lacking A49, indicating that A49 has another function that also 25 
contributes to virulence. Here we demonstrate that gene A49L encodes a second, smaller polypeptide that is 26 
expressed via leaky scanning translation from methionine 20 and is unable to block NF-κB activation. Viruses 27 
engineered to express either only the large protein or only the small A49 protein both have lower virulence than 28 
wild type virus and greater virulence than an A49L deletion mutant. This demonstrates that the small protein 29 
contributes to virulence by an unknown mechanism that is independent of NF-κB inhibition. Despite having a 30 
large genome with about 200 genes, this study illustrates how VACV makes efficient use of its coding potential 31 
and from gene A49L expresses a protein with multiple functions and multiple proteins with different functions.  32 
 33 
Introduction 34 
Vaccinia virus (VACV) has a large dsDNA genome with about 200 genes [1], replicates in the cell cytoplasm [2] 35 
and encodes scores of proteins that inhibit the innate response to infection [3]. The genes encoding these 36 
immunomodulatory proteins are usually non-essential for virus replication in cell culture, but affect virus virulence 37 
and immunogenicity in vivo. This paper concerns one of these non-essential genes called A49L that is encoded 38 
towards the right end of the virus genome. 39 
 40 
A49 is a small, intracellular protein that is expressed early during infection and is non-essential for virus 41 
replication but promotes virus virulence [4]. Crystallography revealed that A49 has a Bcl-2-like fold, and was an 42 
unexpected addition to the family of VACV Bcl-2 proteins [5]. Several cellular anti-apoptotic Bcl-2 proteins have a 43 
surface groove that binds the BH3 peptide of pro-apoptotic Bcl-2 proteins and thereby inhibit their pro-apoptotic 44 
activity. However, A49 lacks this surface groove and, consistent with this, did not bind pro-apoptotic Bcl-2 45 
proteins Bax and Bak [5], which are bound by the closest orthologue of A49, the myxoma virus M11 [6]. 46 
 47 
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The first function assigned to A49 was the inhibition of NF-κB activation by molecular mimicry [4]. Near the N 48 
terminus of A49 there is a short amino acid sequence containing 2 serines (S7 and S12) that are conserved in 49 
several cellular proteins, such as IκBα and β-catenin, and also some virus proteins, such as HIV-1 Vpu. In IκBα 50 
these serines can be phosphorylated, leading to the recognition of p-IκBα by the E3 ligase β-TrCP, and its 51 
consequential ubiquitylation and proteosomal degradation. In turn, this enables release of the NF-κB subunits 52 
into the nucleus and transcription of NF-κB responsive genes. A49 co-precipitates with β-TrCP and this 53 
interaction was abrogated by mutation of S7 and S12 to alanine [4]. By interacting with β-TrCP, A49 prevents β-54 
TrCP-mediated ubiquitylation of p-IκBα, and so IκBα remains bound to the NF-κB subunits in the cytoplasm. 55 
Another substrate of β-TrCP is β-catenin, which was also shown to be stabilised by A49 leading to its 56 
accumulation in cells and the consequential activation of the wnt signalling pathway [7].  57 
 58 
Recently, further insight to the mechanism of action of A49 showed that phosphorylation of S7 was necessary for 59 
A49 to bind β-TrCP and inhibit activation of NF-κB, whereas S12 was dispensable for these functions [8]. 60 
Therefore, A49 is a conditional inhibitor of NF-κB and requires activation by phosphorylation to become an 61 
inhibitor of this pathway. A kinase that phosphorylates A49 S7 was identified as IKKβ, the same kinase that 62 
phosphorylates IκBα and leads to activation of the NF-κB pathway. Consequently, A49 is activated to become an 63 
inhibitor of NF-κB when the pathway leading to NF-κB activation is switched on. In other words, NF-κB activation 64 
is a turn on for A49 to turn off NF-κB activation [8]. This report also showed that A49 has a second function that 65 
contributes to virulence, independent of NF-κB inhibition. VACV strains expressing a mutant A49 protein that 66 
either cannot bind β-TrCP and so cannot inhibit NF-κB activation, or does these functions constitutively, both had 67 
virulence greater than vΔA49 and lower than wild type virus [8]. 68 
 69 
Here another unexpected feature of the A49L gene is described. Data presented show that A49L encodes two 70 
polypeptides that are translated by initiation from either methionine 1 (M1) or methionine 20 (M20) with the same 71 
temporal kinetics. The smaller protein lacking the first 19 aa does not bind β-TrCP and so cannot inhibit NF-κB 72 
activation. Nonetheless, viruses engineered to express only the large or small protein each had reduced 73 
virulence compared to wild type virus and greater virulence than a deletion mutant lacking both proteins. This 74 
showed that the small protein has a function that contributes to virulence and that is not provided by the large 75 
protein. This study illustrates how VACV makes very efficient use of its coding potential. 76 
 77 
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Materials and Methods 78 
Cells and viruses 79 
HEK-293T, CV-1 and BSC-1 cells were grown in Dulbecco modified Eagle’s medium (DMEM, Gibco) 80 
supplemented with heat-treated (56 °C, 1 h) 10% foetal bovine serum (FBS, Harlan-Sera Lab), 100 U/mL 81 
penicillin and 100 µg/ml streptomycin (P&S). RK13 cells were grown in minimum essential medium (MEM) 82 
containing 10% FBS and P&S. Vaccinia virus (VACV) strain Western Reserve (WR) and mutants thereof were 83 
used. A plaque purified wild type virus (vA49R) and a deletion mutant lacking the A49L gene (vΔA49L) were 84 
described [4]. Additional VACVs bearing mutant A49L alleles were constructed by transient dominant selection 85 
[9] starting with vΔA49L as described [8]. Briefly, cells were infected with vΔA49L and then transfected with a 86 
plasmid containing the mutant A49L gene and flanking sequences. Recombinant viruses containing the 87 
transfected plasmid were selected by plaque assay on BSC-1 cells in the presence of mycophenolic acid, 88 
xanthine and hypoxanthine. These intermediate viruses were then resolved to the final recombinant virus by 89 
plaque assay in the absence of drugs and screened for the A49L gene by polymerase chain reaction (PCR). The 90 
A49L gene locus was sequenced for all viruses to confirm the genotype. Stocks of VACV were grown on RK13 91 
cells and titrated by plaque assay on BSC-1 cells. 92 
 93 
Antibodies and cytokines 94 
Tumour necrosis factor alpha (TNFα) and interleukin-1β (IL-1β) were bought from Peprotech. The following 95 
antibodies were used, each diluted 1:1,000: rabbit polyclonal against VACV protein A49 [4], mouse monoclonal 96 
AB1.1 against VACV protein D8 [10]. Mouse monoclonal against anti-α-tubulin (DM1A; Millipore) was used 97 
diluted 1:10,000. 98 
 99 
Reporter gene assay 100 
The activation of the NF-κB pathway was measured by reporter gene assay as described [4]. Briefly, a reporter 101 
plasmid bearing an NF-κB-responsive promoter linked to firefly luciferase was transfected into HEK-293T cells 102 
together with either empty vector (EV) or the same plasmid expressing A49 or mutants thereof. Cells were also 103 
transfected with a plasmid expressing renilla luciferase as a transfection control. The following day cells were 104 
stimulated with 15 ng/mL TNFα for 8.5 h or IL-1β for 8 h (as indicated). Then, cell lysates were prepared and 105 
firefly and renilla luciferase activities were measured. Data are expressed as the firefly activity normalised to the 106 
renilla activity and the fold increase relative to unstimulated control. Three replicates were included for each 107 
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condition and all experiments were conducted three times. Data from a representative experiment are shown. 108 
Statistical analysis compared the fold increase in the presence of EV to individual A49 mutants. 109 
 110 
Mutagenesis 111 
The A49L open reading frame was mutated using the QuickChange Site-Directed Mutagenesis Kit (Aligent) and 112 
the fidelity of all mutants was confirmed by DNA sequencing.  113 
 114 
Polyacrylamide gel electrophoresis and immunoblotting 115 
Extracts of infected or transfected cells were prepared and analysed by SDS-polyacrylamide gel electrophoresis 116 
(SDS-PAGE) and immunoblotting with the indicated antibodies as described [4]. The positions of molecular 117 
mass markers in kDa are shown on the left of each immunoblot. 118 
 119 
In vivo infections 120 
The virulence of the indicated VACVs compared to wild type VACV WR was measured in a murine intranasal 121 
model as described [11]. Groups (n=5) of female BALB/c mice (6-8 weeks old) were infected intranasally (in both 122 
nostrils) under anaesthetic with 5 × 103 plaque-forming units (p.f.u.) of the indicated virus. The titre of the diluted 123 
virus used for infection was determined by plaque assay to confirm the dose administered. The body weight of 124 
each mouse was recorded daily and compared to its weight on day zero. Data for each group are expressed as 125 
the SEM. Each experiment was conducted twice and the data shown are representative. 126 
 127 
Ethics statement 128 
In vivo work was undertaken with approval from the University of Cambridge Ethical Review Board and under 129 
license PPL 70/8524 from the UK Home Office according to the Animals (Scientific Procedures) Act 1986. 130 
 131 
Statistical analysis 132 
Data were analysed by unpaired Student’s t test or a two-way ANOVA test with GraphPad Prism statistical 133 
software (Graph-Pad Software). Statistical significance is expressed as: *P < 0.05, **P < 0.01, ***P < 0.001.  134 
 135 
Conflict of Interest 136 
The authors confirm that they have no conflict of interest relevant to this manuscript.  137 
6 
 
Results 138 
The A49L gene encodes a second polypeptide 139 
A rabbit polyclonal antibody raised against the A49 protein [4] was used to analyse A49 proteins in VACV-140 
infected cells at different times post infection (p.i.) (Figure 1). Immunoblotting showed an A49 protein of ~ 18 kDa 141 
(L) was detected by 2-4 h p.i. This protein was present in the presence of cytosine arabinoside (AraC), and so 142 
was expressed prior to virus DNA replication. The reduced levels in the presence of AraC also indicated 143 
expression late during infection. In addition, a smaller and less abundant protein of ~ 11 kDa (S) was also 144 
detected with the same antibody and appeared with the same kinetics. Immunoblotting for VACV structural 145 
protein D8 with a mouse monoclonal antibody [10] confirmed the effectiveness of AraC in blocking late virus 146 
gene expression, and immunoblotting for α-tubulin confirmed equal loading of samples. Analysis of the A49L 147 
open reading frame revealed a second AUG at codon 20 that might be used to make the smaller protein. 148 
 149 
The smaller A49 protein is made by leaky scanning translation 150 
To address the nature of the smaller protein and determine how it was expressed, the A49L reading frame was 151 
mutated (nucleotide 15 T to A) to introduce a termination codon between M1 and M20 (called stop). An existing 152 
out of frame ATG codon (nucleotides 5-8) was also mutated (ATG to ACG) to prevent any ribosomal initiation 153 
from this position. A second mutant with the same ATG to ACG change and in which the first ATG codon was 154 
mutated to CGA (ΔM1) was also constructed. Plasmids encoding wild type and mutant A49L genes were 155 
transfected into HEK293T cells and protein extracts were analysed by immunoblotting (Figure 2A). This showed 156 
that introduction of a termination codon between the first and second in-frame AUG, or removal of the first AUG, 157 
both prevented expression of the full length A49 protein and enhanced the expression of the smaller protein. 158 
This suggested that after binding to the 5’ cap structure of A49 mRNA, ribosomes scan along the mRNA and 159 
initiate translation from the first available AUG codon. A third mutant in which two additional nucleotides were 160 
introduced between M1 and M20 (A49 out of frame - oof) was also constructed and analysed (Figure 2B). This 161 
allele failed to express the full length protein, as expected, due to switch of reading frame after codon 2 and the 162 
presence of termination codons in the +2 reading frame shortly downstream. Note that the A49 antibody would 163 
also fail to detect any protein made by such a short polypeptide from this different reading frame. However, 164 
consistent with leaky scanning, this allele expressed the smaller protein. 165 
 166 
Mutation of methionine 20 compromises A49 function 167 
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The mutants A49 stop and A49 ΔM1 each made only the small A49 protein, as did another mutant lacking the 168 
first 19 codons (Δ19). To make an allele that made only the larger protein, the M20 codon was mutated to 169 
leucine, alanine, isoleucine or phenylalanine. Transfection of these alleles into HEK293T cells gave expression 170 
of all proteins at similar levels albeit with slightly different electrophoretic mobility (Figure 3B). Next, the ability to 171 
these alleles to inhibit NF-κB activation was measured by reporter gene assay (Figure 3A). Surprisingly, all the 172 
mutants with M20 changed to another amino acid, lacked the ability to inhibit NF-κB activation, despite retaining 173 
the upstream residues (including S7) needed for interaction with β-TrCP. The Δ19 mutant was also unable to 174 
inhibit the pathway as expected (Figure 3A). The virulence of the A49 M20L protein was analysed in vivo after 175 
insertion of this mutant allele into the VACV lacking the A49L gene (vΔA49) [4]. As observed previously [4, 8], 176 
the vΔA49 mutant was attenuated compared to the WT virus, as shown by reduced weight loss after intranasal 177 
infection of Balb/c mice. Surprisingly, the A49 M20L mutant virus had a virulence equivalent to its parent virus 178 
vΔA49, indicating that the larger A49 protein with M20L did not contribute to virulence and seemed non-179 
functional. This result prevented a comparison of the contribution of the large and small A49 proteins to virulence 180 
and so additional mutants were designed. 181 
 182 
A mutant making only the large A49 protein 183 
All A49 mutants with M20 altered to another amino acid were unable to inhibit NF-κB activation and A49 M20L 184 
made no contribution to virulence in vivo. Therefore, an alternative mutant that made only the larger protein was 185 
designed. To prevent expression of the smaller protein an additional ATG codon was created between codon 1 186 
and 20 that was out of frame with the A49 reading frame. Ribosomes failing to initiate translation at codon 1 187 
would now scan the mRNA and initiate translation from the new AUG codon (nucleotides 47-49) rather than 188 
codon 20. This mutant is called out of frame ATG (oof ATG). This new initiation codon has a sub-optimal Kozak 189 
consensus sequence, and this was strengthened by substitution of nucleotide 50 from T to G. This change also 190 
caused a conservative amino acid substitution in the large protein (V17G) so this mutant was called oofATG 191 
V17G (Figure 4C). The expression and function of these mutant proteins was tested by transfection of plasmids 192 
containing these alleles followed by immunoblotting, and by reporter gene assay (Figure 4A, B). This showed 193 
that oofATG and oofATG V17G each expressed only the larger protein and at levels similar to WT. The reporter 194 
gene assay showed that oofATG inhibited activation of NF-κB, whereas oofATG V17G and M20L did not.  195 
 196 
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Expression of these mutant A49 alleles from plasmid vectors showed that oofATG and oofATG V17G each 197 
expressed only the full length protein. However, when the oofATG allele was introduced into the vΔA49 VACV 198 
and the expression of A49 was examined, a low level of expression of the small A49 protein remained 199 
(Supplementary Figure). The only difference between the sequences of the oofATG allele in the plasmid and the 200 
virus was the presence of a T at the -3 position in the virus and an A at the -3 position in the plasmid. Since the 201 
presence of an A at -3 strengthens the Kozak consensus sequence, a virus (SoA) was engineered to have A 202 
rather than T at nucleotide -3. Analysis of the expression of the A49 proteins from cells infected by this virus 203 
showed that only the large protein was present (Figure 5). A trace band at the same position as the small protein 204 
was detected, but this was also seen in cells infected with the A49 deletion mutant and therefore represents a 205 
background cross-reacting band. 206 
 207 
Both the large and small A49 proteins contribute to virulence 208 
Now that viruses expressing only the large A49 protein (SoA), only the small A49 protein (A49Δ19), neither 209 
protein (vΔA49), or both proteins (WT) were available, the contributions of the two proteins to virulence was 210 
examined in vivo (Figure 6). This showed that the virulence of viruses expressing only the small protein, or only 211 
the large protein, were greater than the deletion mutant and lower than the WT virus, and therefore both proteins 212 
contribute to virulence. Since the smaller protein cannot inhibit NF-κB, it must contribute to virulence by an 213 
independent mechanism. Similarly, the large protein alone is a virulence factor but lacks something that the 214 
smaller protein provides. This might be explained by the N-terminal 19 amino acids masking some part of A49 215 
that would otherwise be exposed and have a function that promotes virulence. 216 
 217 
Discussion 218 
The VACV genome encodes about 200 genes and so is large in comparison with many DNA and all RNA 219 
viruses. Yet, despite this, the virus utilises its coding capacity efficiently by having tightly packed genes, no 220 
introns and many multi-functional proteins. The A49L gene of VACV WR is a good example of this efficient use 221 
of coding capacity. Previously, the A49 protein was shown to inhibit the activation of NF-κB and promote 222 
activation of the wnt signalling pathway by engaging the E3 ubiquitin ligase β-TrCP [4, 7]. Interaction with β-223 
TrCP stabilises substrates of β-TrCP such as IκBα and β-catenin that otherwise would be ubiquitylated and 224 
degraded. However, this is not the only function of A49. Evidence for an additional function came from analysis 225 
of a virus expressing a mutant A49 protein that can neither engage β-TrCP, nor block NF-κB activation. This 226 
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virus had a virulence greater than vΔA49 but less than WT virus [8], indicating A49 has another function. 227 
Consistent with this, a virus expressing A49 that binds β-TrCP constitutively has reduced virulence compared to 228 
WT virus, suggesting that being free to interact with other substrates might also be important for virulence [8]. 229 
 230 
Here, an additional feature of the A49L gene is described. In addition to encoding a full length protein of 162 231 
amino acids, the A49L gene also expresses a smaller protein that is expressed by translational initiation from 232 
M20 of the larger protein. This smaller protein is less abundant than the full length A49 protein, but is expressed 233 
with the same temporal kinetics. Removal of the N-terminal 19 amino acids, mutation of the first AUG codon, or 234 
creation of a stop codon between the AUG codons at position 1 and 20, all resulted in expression of only the 235 
smaller protein that is unable to inhibit NF-κB activation because it lacks the conserved motif SGXX(X)S (amino 236 
acids 7-12 in A49) that is present in β-TrCP substrates. Nonetheless, a mutant virus expressing only the smaller 237 
A49 protein had greater virulence than the A49 deletion mutant, showing that the smaller protein has another 238 
function that contributes to virulence independent of NF-κB inhibition. 239 
 240 
Attempts to engineer a virus that expressed only the large A49 protein (and which was functional) were thwarted 241 
by the unexpected finding that mutation of M20 to either A, F, I or L all resulted in an A49 protein that was unable 242 
to inhibit NF-κB, and, in the case of M20L, did not contribute to virulence (the other mutants were not tested). 243 
Further mutations in this short N-terminal region, such as V17G (Figure 4) or L10V (unpublished data), also 244 
resulted in loss of inhibition of NF-κB activation. Therefore, an alternative strategy to prevent expression of the 245 
small A49 protein was used. An additional (out of frame) AUG codon was introduced between codon 1 and 246 
codon 20, so preventing access of ribosomes to the codon 20 AUG. This, together with mutation of the -3 247 
position of codon 1 to strengthen the Kozak consensus sequence [12], resulted in a virus that only made the 248 
large A49 protein of wild type sequence. In a murine intranasal model, this virus had greater virulence than the 249 
deletion mutant, but lower virulence than WT virus. Therefore, although the large A49 protein includes the entire 250 
sequence of the smaller protein, it cannot undertake some function of the small protein that contributes to 251 
virulence. This function is unknown but is independent of β-TrCP binding and modulation of the NF-κB and wnt 252 
signalling pathways. 253 
 254 
Collectively, these data show that the A49L gene encodes a full length protein with multiple functions, and 255 
multiple proteins with different functions. This remarkable efficient use of coding capacity might be considered 256 
10 
 
unusual for a large DNA virus, but may not turn out so as the functions of individual genes and proteins of these 257 
viruses are studied in greater depth. As mentioned in the introduction, the A49 protein is a member of the VACV 258 
family of Bcl-2 proteins [5]. There are 11 members of this family and the majority of these small alpha helical 259 
proteins have multiple functions in immune evasion. Examples include: the N1 protein that has anti-apoptotic 260 
and NF-κB inhibitory activity [13-15]; the F1 protein that inhibits apoptosis and activation of the inflammasome 261 
[16-18]; the B14 protein that inhibits NF-κB activation [19] but also has another function that contributes to 262 
virulence (unpublished data); the K7 [20-22] and A46 [23-27] proteins that each inhibit activation of both the IRF-263 
3 and NF-κB pathways; and the C6 protein that inhibits activation of both the IRF-3 pathway [28] and the JAK-264 
STAT pathway downstream of type I interferon binding to its receptor [29], and induces proteolytic degradation of 265 
histone deacetylases 4 and 5 [30, 31]. 266 
 267 
Outside of the Bcl-2 family, other VACV proteins engaged in immune evasion also have multiple functions. 268 
Examples include protein E3 that binds dsRNA via its C-terminal domain and prevents dsRNA-dependent 269 
activation of protein kinase R [32] and 2’-5’-oligoadenylate synthetase [33]. The N-terminal region has a Z-DNA 270 
binding domain [34] and via this domain inhibits DAI-dependent necroptosis [35]. Both domains contribute to 271 
virus virulence [36]. Other multifunctional VACV proteins are the related proteins C16 and C4. Protein C16 272 
inhibits Ku-mediated DNA sensing via its C-terminal domain [37] and induces a hypoxic response by binding the 273 
oxygen sensor PHD2 via its N-terminal domain [38] leading to reprogramming of cellular energy metabolism [39]. 274 
Protein C4 inhibits NF-κB activation [40] and the Ku-mediated DNA sensing [41]. Protein A55 is another 275 
multifunctional, multi-domain protein. A55 binds cullin 3 via its N-terminal BTB domain [42, 43], and inhibits NF-276 
κB by binding to the importin KPNA2 to prevent p65 translocation into the nucleus [43]. Another multifunctional 277 
orthopoxvirus protein, which is secreted from the cell, is the protein G2 of variola virus (VARV), the cause of 278 
smallpox. This protein, and orthologues in monkeypox virus and cowpox virus, binds TNF via its N-terminal 279 
cysteine-rich domain and chemokines via a C-terminal domain [44]. 280 
 281 
While many proteins are multi-functional, few VACV genes encode multiple proteins. One example is the E3L 282 
gene that, like A49, encodes two different proteins that differ at their N-termini due to translational initiation from 283 
different in frame AUG codons [45]. Both the 25-kDa and 19-kDa E3 proteins contain the C-terminal dsRNA 284 
binding domain, but a function for the smaller protein not performed by the larger protein has not been 285 
described, and its biological importance is unknown. Other VACV genes encode proteins that are cleaved 286 
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proteolytically, for instance during capsid maturation, to give distinct polypeptides. In addition, to the proteins 287 
predicted to be encoded by the VACV genome from analysis of the genome sequence [1], ribosomal profiling 288 
provided evidence for translation of additional VACV polypeptides [46]. Interestingly, the shorter polypeptides 289 
encoded by the E3L and A49L genes were not detected by this technology. 290 
 291 
In summary, the VACV A49L gene is shown here to encode 2 different proteins that are expressed by 292 
translational initiation from different in frame AUG codons. Both proteins contribute to virus virulence and 293 
although the sequence of the smaller protein is present entirely within the larger protein, it has an unknown 294 
function the larger protein does not provide. 295 
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Figure legends 301 
Figure 1. Two proteins are encoded from the A49L gene. HEK-293T cells were infected with VACV WR at 5 302 
p.f.u. / cell. Where indicated 40 µg/ml cytosine arabinoside was added. At 2, 4, 6 or 8 h p.i. cells were harvested 303 
and cell extracts were analysed by SDS-PAGE and immunoblotting with antibodies to the VACV proteins A49 304 
and D8 and cellular α-tubulin. Red arrows mark the positions of the large (L) and small (S) A49 proteins and the 305 
star marks a nonspecific signal also present at zero h. 306 
 307 
Figure 2. The A49 S protein is expressed by leaky scanning translation. A) Immunoblot. HEK-293T cells were 308 
transfected with plasmids encoding WT A49 or mutants (as shown in B). The following day cell extracts were 309 
prepared and analysed by SDS-PAGE and immunoblotting with antibodies against A49 (top) and α-tubulin 310 
(bottom). Red arrows mark the large (L) and small (S) A49 proteins. B) Nucleotide sequence of the WT and 311 
mutant A49 alleles used in A) starting from the ATG codon 1 of the full length open reading frame. Positions 312 
mutated from the WT sequence are shown in red. A49 stop contains an in frame termination codon at 313 
nucleotides 13-15 and a T to C substitution at nucleotide 6 to remove an out of frame ATG codon. A49 ΔM1 has 314 
the ATG codon (positions 1-3) changed to CGA, and the same T to C change at position 6 as for A49 stop. A49 315 
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oof (out of frame) has an insertion of 2 nucleotides after nucleotide 6 to put the ATG codons at codon 1 and 20 in 316 
different reading frames. 317 
 318 
Figure 3. Mutation of methionine 20 abrogates A49 L function. A) Reporter gene assay. HEK-293T cells were 319 
transfected with empty vector (EV), or plasmids expressing WT A49 or mutant A49 proteins either lacking the N-320 
terminal 19 aa (Δ19) or with M20 changed to L, A, I or F (M20L, M20A, M20I, and M20F). The following day, 321 
cells were stimulated (black bars) with TNF-α (15 ng/ml for 8.5 h) and then lysates were prepared and the renilla 322 
and firefly luciferase activity were measured. Data presented are the mean of the firefly luciferase activity 323 
normalised to the renilla luciferase activity (each in triplicate), which were then normalised to unstimulated EV ± 324 
SD. ** p<0.01 compared to stimulated EV. B). Immunoblot. Cell extracts, prepared as in A), were analysed by 325 
SDS-PAGE and immunoblotting with antibodies against VACV protein A49 (top) or α-tubulin (bottom). C) 326 
Virulence measurement of VACVs. Groups (n=5) of female BALB/c mice were infected intranasally with 5 × 103 327 
p.f.u. of indicated VACVs or were mock-infected (mock) and the weight of each mouse was measured daily. The 328 
weight of each mouse was compared to its weight on day zero and data are presented as the mean ± SEM for 329 
each group. Statistical analysis was by two way ANOVA test. Data from A49M20L and vΔA49 were each 330 
significantly different from A49WR (p = 0.0001 WR versus vΔA49, and p = 0.001 WR versus vM20L) but were 331 
not significantly different from each other. 332 
  333 
Figure 4. Analysis of A49 alleles making either only the large or small protein. A) Reporter gene assay using 334 
plasmids described in C) and in Figures 2 and 3, and conducted as described in Figure 3. B) Immunoblot 335 
showing expression of the different A49 proteins using extracts from cells prepared as in A). C) Nucleotide 336 
sequence of WT A49 and mutants. Changes from the wild type sequence are shown in red. The top 3 rows are 337 
sequences present in plasmids expressing these A49 alleles and the bottom 2 rows show the sequence of WT 338 
or SoA (strong 1st ATG in oofATG) mutant virus. oofATG (out of frame ATG) is mutated to create an ATG codon 339 
at nucleotides 47-49, between the ATG codons at positions 1 and 20. V17G is like oofATG but also has 340 
nucleotide 50 changed from T to G to give the new ATG codon a stronger Kozak consensus sequence. SoA has 341 
the T at position -3 changed to A to give the codon 1 AUG a stronger Kozak consensus sequence. 342 
 343 
Figure 5. Expression of A49 proteins in cells infected with VACVs. HEK-293T cells were infected at 5 p.f.u. / cell 344 
with WT VACV (vWT) or viruses designed to make neither A49 protein (vΔA49), only the large (L) protein 345 
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(vA49SoA), or only the small protein vA49Δ19. At 16 h p.i. cells were harvested and cell extracts were analysed 346 
by SDS-PAGE and immunoblotting with antibodies to VACV proteins A49 and D8 or α-tubulin. Red arrows 347 
indicate the positions of the large (L) or small (S) A49 proteins.  348 
 349 
Figure 6. Virulence of VACVs. Groups of mice were infected with the indicated viruses as in Figure 3C and were 350 
weighed daily. Data were analysed and are expressed as described in Figure 3C. Statistical analysis was by two 351 
way ANOVA test. Groups vA49Δ19 and vA49SoA were not significantly different from each other, but were each 352 
significantly different from both vΔA49 and A49WR (p = 0.01 soA vs WR and soA versus vΔA49).  353 
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